IOL Chemicals and Pharmaceuticals Limited — Investor Meet, 18-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

**Financial Performance:** IOL Chemicals and Pharmaceuticals recorded total income of Rs. 527 Cr in Q3 FY25, slightly down from Rs. 529 Cr year-on-year. EBITDA stood at Rs. 51 Cr with a margin of 9.7%, down from 10% in the same quarter last year. Net profit was Rs. 21 Cr, reflecting a decline from Rs. 23 Cr in Q3 FY24. The pharmaceutical segment's EBIT margin was 8.7%, while the specialty chemicals segment reported 2.1%. CAPEX for the quarter amounted to Rs. 54 Cr.

**Future Outlook and Growth Drivers:** Management noted challenges from consumption slowdown and pricing pressures but expressed optimism as government tax reliefs could support demand. Expectations of recovery in demand and easing prices were mentioned for Q1 of next year, anticipating growth driven by operational efficiencies.

**Order Book and Operational Updates:** The company is exploring new customers in the U.S. market, with initial benefits expected in the next 2-3 quarters. Current capacity utilization for ibuprofen is around 75%, with a target of 90% in the near term.

**Analyst Q&A Insights (Detailed):** Analysts questioned revenue forecasts due to declining prices in the API segment. Management confirmed margins for ibuprofen are stable and hinted at potential recovery. Concerns regarding new competitors entering the ibuprofen market were downplayed, and management reiterated that the long-term guidance suggests potential for a modest EBITDA margin improvement of around 13%-15% in the coming years.

**Market or Regulatory Updates:** There were discussions regarding the extensive timeline for U.S. FDA inspections, with management indicating preparedness despite delays.

**Strategic Focus Areas:** Management's emphasis remains on improving capacity utilization and expanding export markets, particularly in Europe and LATAM, along with diversifying their product offerings.

**Investor Insight:** Given the current financial trends and management’s cautious optimism, the company's position appears to lean towards holding, with potential for future growth tied to recovery in demand and operational efficiencies. Investors should be aware of ongoing risks such as pricing pressures and regulatory uncertainties.